Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2 Mutated Meningiomas

NCT05130866 is registered in ClinicalTrials.gov with Recursion Pharmaceuticals Inc. as lead sponsor.

NCT NCT05130866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05130866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2 Mutated Meningiomas
Lead sponsor
Recursion Pharmaceuticals Inc.
Phase
Phase 2/3
Overall status
Terminated
Start date
June 20, 2022
Completion date
August 18, 2025
Enrollment
25 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

neurofibromatosis type 2